1. Introduction to Organoids
1.1 Organoids
1.2 History of the Development
1.3 Timeline for Patient Derived Tumor Organoid (PDTO) Development
2. Cancer Organoids: Promising Tool for Cancer Biologists
2.1 Cancer Organoids Revealing the Cancer Dynamics
2.2 Cancer Organoids: An Intermediate Platform for Targeted Therapy
3. Human Cancer Modeling
3.1 Growth Factors and Small Molecule Inhibitors Applied In Organoid Cultures
3.2 Culture Systems of Multiple Tumoroids
3.3 Human Organoid Protocol
3.4 Extraction Methods for Initiating an Organoid Generation
3.4.1 Biopsy
3.4.2 Surgery
4. Establishment of Cancer Organoids
4.1 In-vitro Establishment of Stomach Cancer Organoid Cancer
4.2 Invasion of In-Vivo Mutations in In-Vitro Organoid Model of Intestinal Cancer
4.3 Expansion of Liver Cancer Organoids in the Laboratories
4.4 In- Vitro Modeling of Pancreatic Cancer Organoid
4.5 Transformation of Breast Cancer Cells into Organoids
4.6 3D Organoid Model Generation for Bladder Cancer
4.7 Obtaining In-Vitro Model of In-Vivo Prostate Cancer
4.8 Miniature Organ Development from the In-Vivo Ovarian Cancer Cells
4.9 Creation of In-Vivo Esophageal Cancer as an In-Vitro Organoid Model
5. Cancer Organoids and Other Laboratory Techniques to Assess Treatment Responses
5.1 Cell Lines
5.2 Patient-Derived Xenografts
5.3 Organotypic Tissue Slice Culture
5.4 Cancer Organoids: Marking a New Territory
6. Tumors Organoids Accelerating Cancer Treatment
6.1 Cancer Epidemic and Pre-Screening
6.2 Cancer Organoids Predicting Tumor Responses
7. Advantages of Cancer Organoids
7.1 Reduction in Experimental Complexity Through Cancer Organoids Models
7.2 Similar Genetic Representation between the Organoid and Parent Tumor Organ
7.3 Cancer Organoid Models Predicting the Response of Cancer Treatment
7.4 Cancer Organoid Models Retaining the Phenotype of Parent Organ after Development
7.5 Cancer Organoid Models Supporting Biomarker Profiling in Cancer Research
8. Cancer Organoids: Advanced Research and Therapeutic Potential
8.1 Cancer Organoids: Revolutionizing Novel Anti-Cancer Drug Testing Methodology
8.2 Mini-Organ Toxicity Demonstration by Cancer Organoids
8.3 Pharmacokinetics and Pharmacodynamics Analysis Enabled by Cancer Organoids
8.4 Cancer Organoids: Innovations in Drug Development Method
8.5 Cancer Organoids as a Potential Platform for Personalized Cancer Therapy
9. Organoid Development Transforming Basic Medical Research
9.1 Organoids Advancement in Organ Replacement
9.2 Analyzing Gene Therapy on Organoids
9.3 Organoids for Cell Therapy Analysis
10. Post-Model Generation Screening of Cancer Organoids
10.1 Identical Genetic Characteristics between Cancer Organoid and Parent Organ
10.2 Maintaining the Histology of Cancer Organ Tissues
10.3 Tumorigenic Characteristic Screening of Cancer Organoids
11. Patient-Derived Tumor Organoids and its Achievement in Medical Research
11.1 Translational Application of Cancer organoid Models
11.2 Cancer Organoids Promoting Oncogenic Mutation Study
11.3 Integration of the Microenvironment Induced by Cancer Organoids
12. CRISPR-Cas9 Potential Applications in Cancer Organoids
12.1 CRISPR-Cas9: A Promising Gene Editing Technology
12.2 CRISPR-Cas9 Mediated Cancer Organoid Technology
12.3 CRISPR Based Gene Edited Organoids Recapitulating Cancer Mutations
13. Organoids for the Study of Pancreatic Cancer
13.1 Human Endocrine and Exocrine Cancer Pancreatic 3D Model to Transform Cancer Treatment
13.2 Development of Pancreas 3D Cancer Organoid System
13.3 Applications of 3D Pancreatic Organoid Culture
13.3.1 Pancreatic Cancer Organoid and Genetic Implementation
13.3.2 Pancreatic Cancer Organoid and the Inner Environment Benefits
13.3.3 Pancreatic Cancer Organoid Model for Drug Toxicity Screening
13.3.4 Pancreatic Cancer Organoid Provoking Personalized Therapy
14. Organoids for the Study of Stomach Cancer
14.1 Development of Stomach Cancer Organoid Culture
14.2 High-Throughput Screening with Stomach Cancer Organoid 3D Model
14.2.1 Tumorigenesis with Stomach Cancer Organoids
14.2.2 Stomach Cancer Organoids Screening Drug Sensitivity
14.2.3 Developing Stomach Cancer Biobanks for Drug Screening
14.2.4 Stomach Cancer Organoids for Personalizing Therapy
15. Three-Dimensional Culture of Liver Organoid in Cancer Biology
15.1 Development of Liver Organoids
15.2 Progress and Potential of Organoid Towards Liver Cancer
15.2.1 Liver Cancer Organoids as a New Model for Improving Drug Screening
15.2.2 Primary Liver Cancer Organoids for Novel Drug Discovery
15.2.3 Primary Liver Cancer Organoids Creating the Living Biobank for the Future Therapeutic Challenges
15.2.4 Primary Liver Cancer Organoids Transforming Personalized Therapy
16. Advanced Development of Breast Cancer Organoids
16.1 Organoid Technology to Transform Breast Cancer Modeling and Development
16.2 An Organoid Approach Marking Breast Cancer Therapeutic Research
16.2.1 Breast Cancer Organoids in Drug Development and Expansion
16.2.2 Breast Cancer Organoids: An in-vitro Model for Cancer Biomarker Discovery
16.2.3 Breast Cancer Organoids as a Powerful Resource for Personalized Therapy
17. Kidney Cancer Organoids for Cancer Research and Therapeutic Challenges
17.1 Kidney Cancer Organoids: Developmental Approach and Characteristics Analysis
17.2 Organoid Technology and its Applications in Treating Kidney Cancer
17.2.1 Kidney Cancer Organoids Actively Participating in the Pre-Clinical and Clinical Trials
17.2.2 Validation of Cancer Biomarkers by Kidney Cancer Organoids in Drug Development
18. Organoids for the Development of Lung Cancer
18.1 Generation of Lung Cancer Organoid from Lungs Tissue
18.2 Lung Cancer Organoids: A Novel 3D Platform for Therapeutic Research
18.2.1 Lung Cancer Organoids for Therapeutic Screening and Cancer Research
18.2.2 Organoids Re-Creating the Treatment for Lung Cancer
19. Ovarian Cancer Organoids and its role in Therapeutic Advancement
19.1 Organoid Model Recapitulating Human Ovarian Cancer
19.2 Validation of Potential Benefits Received from Patient-Derived Ovarian Cancer Organoid Model
19.2.1 Editing of Oncogenes in the Patient Derived Ovarian Cancer Organoids
19.2.2 Screening and Drug Testing on Human Ovarian Cancer Organoid Model
19.2.3 Ovarian Cancer Organoids in Modeling the Ovarian Cancer Development and Progression
20. An Organoid Platform for Oncological Research in Bladder Cancer
20.1 Establishment of High-Resolution 3D Organoid Model for Bladder Cancer
20.2 Efficient Use of 3D Bladder Cancer Organoids in Oncology Landscape
20.2.1 3D Bladder Cancer Organoids at an Uprising Scale for Drug Discovery
20.2.2 Testing and Screening of Drugs using Bladder Cancer Organoids
20.2.3 Patient-Derived Bladder Cancer Organoids Predicting Response to Various Cancer Treatments
21. Human Primary Head and Neck Cancer: An Organoid Approach for In-depth Clinical Research
21.1 Generation and Culture of 3D Head and Neck Cancer Organoids
21.2 Patient-Derived Head and Neck Cancer Organoids Re-defining the Cancer Research
21.2.1 Broad Activity of Head and Neck Cancer Organoids towards Cancer Modeling
21.2.2 Transformation of Drug Development and Drug Efficacy Strategies in Head and Neck Cancer using Organoid Technology
22. Living Biobanks of Cancer Organoids Representing Histopathological Diversity
22.1 The Potential of Living Biobank towards Precision Medicine
22.2 Living Bio-banking Strategy Offering Novel Therapeutics for Basic and Advanced Cancer Research
23. Drivers and Challenges Associated with Cancer Organoids
23.1 Drivers Witnessing the Growth of Cancer Organoid Technology
23.2 Challenges Concerning the Growth of Cancer Organoids
24. Future Directions of Organoids in Cancer Research
25. Strategic Joint Ventures by Pharma Companies to Accelerate Drug Discovery through Organoids
25.1 Expanded Breast Cancer Organoids License Agreement between Cellesce and Hubrecht Organoid Technology
25.2 Pre-Clinical Anti-Cancer Drug Development between HUB Organoid Technology and Crown Biosciences
25.3 SEngine’s and Atomwise’s New Joint Venture to Boost Drug Discovery through Organoids
26. Clinical Trials Registered under Cancer Organoids
26.1 Lung Cancer
26.1.1 Clinical Trial – Patient-Derived Organoids of Lung Cancer to Test Drug Responses
26.1.2 Clinical Trial – Patient-Derived Organoid Model and Circulating Tumor Cell for Treatment Responses of Lung Cancer
26.1.3 Clinical Trial – Drug Sensitivity Correlation between Patient-Derived Organoid Model and Clinical Responses in Non-Small Cell Lung Cancer Patients
26.2 Breast Cancer
26.2.1 Clinical Trial – Clinical Study on Drug Sensitivity Verification or Prediction for Breast Cancer by Patient-Derived Organoid Model
26.3 Pancreatic Cancer
26.3.1 Clinical Trial – Drug Screening of Pancreatic Cancer Organoids Developed from EUS-FNA Guided Biopsy Tissues
26.4 Esophageal Cancer
26.4.1 Clinical Trial – Chemoradioresistnace in Prospectively Isolated Cancer Stem Cells in Esophageal Cancer – Organoid: RARE STEM Organoid
27. Current Market Scenario of Cancer Organoid Technology
27.1 Market Trends
27.2 Market Overview
27.2.1 North America
27.2.2 Europe
27.2.3 Asia-Pacific
28. Competitive Landscape
28.1 Cellesce
28.2 MIMETAS
28.3 Hubrecht Organoid Technology
28.4 Crown Biosciences
28.5 Atomwise
28.6 STEMCELL Technologies
28.7 Qgel
28.8 OcellO
28.9 DefiniGEN
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/